Skip to content

TRV GP IV, LLC

Follow

13F filer, CIK 1688325, Boston, MA

TRV GP IV, LLC reported $149,734,299 across 2 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16.

Accepted , ingested 13F-HR 0001193125-26-463545

Period
2026-09-30
Reported value
$150M
Holdings
2
Top 10 weight
100%
New
0
Sold out
0

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
TNGXreduced-4,430,000-$111M
MAZEreduced-750,000-$20.4M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001193125-26-463545, largest first. % of portfolio is the value over $149,734,299, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
MAZEMAZE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 6,073,958 shares; 2025Q2: 6,073,958 shares; 2025Q3: 6,073,958 shares; 2025Q4: 4,473,958 shares; 2026Q1: 4,473,958 shares; 2026Q2: 4,473,958 shares; 2026Q3: 3,723,958 shares 3,723,958$101M67.6%-750,000Timeline
TNGXTANGO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 16,859,075 shares; 2025Q1: 16,859,075 shares; 2025Q2: 16,859,075 shares; 2025Q3: 13,863,975 shares; 2025Q4: 7,874,574 shares; 2026Q1: 6,374,574 shares; 2026Q2: 6,374,574 shares; 2026Q3: 1,944,574 shares 1,944,574$48.5M32.4%-4,430,000Timeline

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001193125-26-463545 base2026-11-16